U.S., July 10 -- ClinicalTrials.gov registry received information related to the study (NCT07691593) titled 'Neoadjuvant HRS-4642 Plus Chemotherapy With or Without Immunotherapy for Pancreatic Cancer' on June 29.
Brief Summary: To evaluate the safety and efficacy of neoadjuvant HRS-4642 plus chemotherapy with or without adebrelimab in patients with pancreatic ductal adenocarcinoma.
Study Start Date: June, 2026
Study Type: INTERVENTIONAL
Condition:
Pancreatic Cancer
Intervention:
DRUG: HRS-4642+NALIRIFOX
HRS-4642+NALIRIFOX
DRUG: HRS-4642+NALIRIFOX+Adebrelimab
HRS-4642+NALIRIFOX+Adebrelimab
DRUG: HRS-4642+NALIRIFOX+Adebrelimab
HRS-4642+NALIRIFOX+Adebrelimab
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Changhai Hospital
Publi...